Healthcare
Live Price
Offline$10.53
+3.24% today
1Y Change
+41.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Varex Imaging Corporation (VREX) is a Healthcare stock with a market cap of $490.00M and listed on NASDAQ. The stock last traded around $10.53 and up 41.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +4.1%, EPS growth of -45.3%, a dividend yield of 0.0%. What stands out right now is revenue +4.1%, EPS -45.3%, free cash flow -7.8% with operating margin -2.8% and ROIC -2.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VREX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VREX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VREX Max Drawdown
-35.10%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VREX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$818.1M
-4.8% YoY
FY Net Income
$17.4M
-42.6% YoY
Free Cash Flow
$77.5M
+1861.4% YoY
Revenue Growth
+4.1%
EPS Growth
-45.3%
Gross Margin
34.2%
Net Margin
-7.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 845M | 811M | 893M | 859M | 818M |
| Gross Profit | 291M | 257M | 290M | 284M | 272M |
| Operating Income | -28M | 32M | 77M | 88M | 74M |
| EBITDA | 4M | 63M | 95M | 115M | 105M |
| Net Income | -70M | -48M | 48M | 30M | 17M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 145M | 169M | 153M | 89M | 145M |
| Total Assets | 1.1B | 1.2B | 1.2B | 1.2B | 1.1B |
| Total Liabilities | 621M | 668M | 669M | 638M | 651M |
| Shareholder Equity | 473M | 535M | 568M | 533M | 483M |
| Total Debt | 402M | 470M | 470M | 436M | 459M |
| Net Debt | 257M | 302M | 317M | 347M | 315M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
93M
+447.9% YoY
Capital Expenditures
15M
+29.1% YoY
Free Cash Flow
78M
+1861.4% YoY
Key ratios
Gross Margin
34.2%
Operating Margin
-2.8%
Net Margin
-7.9%
ROE
-13.9%
Debt / Equity
0.84x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.